Quick access to main page (top) Direct access to main contents Quick access to main page (bottom)

New Hope for Non-Hodgkin’s Lymphoma Patients: Verismo’s SynKIR-310 Enters Clinical Trial Phase

Daniel Kim Views  

Verismo Therapeutics, a U.S. subsidiary of HLB developing next-generation CAR-T cell therapies, announced on the 5th that it has submitted a Phase 1 clinical trial plan (IND) to the U.S. Food and Drug Administration (FDA) for SynKIR-310, a treatment for recurrent/refractory non-Hodgkin’s lymphoma.

The clinical trial will target patients with various types of lymphoma, including diffuse large B-cell lymphoma (DLBCL), a type of blood cancer, and recurrent, refractory B-cell non-Hodgkin’s lymphoma (NHL).

While currently approved CAR-T therapies have a high response rate in blood cancers, over time, relapse occurs in 40-50% of patients, highlighting a clear limitation. Moreover, the treatment options are extremely limited for patients who relapse after receiving CAR-T therapy, as traditional CAR-T treatments no longer show therapeutic effects.

According to Verismo, co-founders and University of Pennsylvania (UPenn) professors Dr. Donald Siegel and Dr. Michael Milone have successfully developed a unique CD19 binder (DS191) that targets CD19, a key target antigen of B-cell-derived cancer. Combining this with Verismo’s multi-chain KIR-CAR platform, it is expected to remain activated longer than existing CAR-T cells and effectively suppress cancer recurrence while demonstrating effective anti-cancer effects.

Dr. Laura Johnson of Verismo, who planned this clinical trial, said, “SynKIR-310 can provide a new treatment option for patients who are difficult to treat with existing CAR-T therapies, especially those with recurrent, refractory B-cell non-Hodgkin’s lymphoma. We expect it to effectively prevent early cancer recurrence by enhancing the resistance of aggressive lymphoma patients and the anti-cancer function of T-cells.”

Daniel Kim
content@viewusglobal.com

Comments0

300

Comments0

[LATEST] Latest Stories

  • Pfizer Ends Obesity Drug Trial After Liver Risk Emerges
  • Not Just Old Age: The Pneumonia That Affected Pope Francis’ Final Years
  • China Just Cranked U.S. Tariffs to 84% — And That’s Not the End of It
  • BMW's Next-Gen EV: The Bold New i3 Touring Concept Revealed
  • LEGO Technic Ferrari SF-24 F1 Car: A 1,361-Piece Tribute to Ferrari’s 2024 F1 Season
  • Hyundai’s Ioniq 6 Just Took the Top Spot in J.D. Power’s EV Ownership Study

You May Also Like

  • 1
    Prunes: The Underrated Superfruit Your Cardiologist Might Approve Of

    LIFESTYLE 

  • 2
    3 Daily Habits That Might Be Aging Your Brain Faster Than You Think

    LIFESTYLE 

  • 3
    The One-Spoon Habit That’s Taking Over Healthy Mornings

    LIFESTYLE 

  • 4
    Tired of Painful Periods? Your Pantry Might Hold the Cure

    LIFESTYLE 

  • 5
    Still Tired After 8 Hours of Sleep? This Could Be Why

    LIFESTYLE 

Popular Now

  • 1
    Scientists Link Let-7 Gene to Lung Healing—and Possibly a Cure for Fibrosis

    LIFESTYLE&nbsp

  • 2
    GLP-1 Drugs Like Ozempic Might Cut Cancer Risk Too, Study Finds

    LIFESTYLE&nbsp

  • 3
    New Brain Cancer Drug Taps Into the Body's Internal Clock

    LIFESTYLE&nbsp

  • 4
    How What You Eat Affects Your Mouth—And the Rest of Your Body

    LIFESTYLE&nbsp

  • 5
    Fatigue Fighters? Scientists Zero In on Hidden Energy Regulators

    LIFESTYLE&nbsp

Must-Reads

  • 1
    Prunes: The Underrated Superfruit Your Cardiologist Might Approve Of

    LIFESTYLE 

  • 2
    3 Daily Habits That Might Be Aging Your Brain Faster Than You Think

    LIFESTYLE 

  • 3
    The One-Spoon Habit That’s Taking Over Healthy Mornings

    LIFESTYLE 

  • 4
    Tired of Painful Periods? Your Pantry Might Hold the Cure

    LIFESTYLE 

  • 5
    Still Tired After 8 Hours of Sleep? This Could Be Why

    LIFESTYLE 

Popular Now

  • 1
    Scientists Link Let-7 Gene to Lung Healing—and Possibly a Cure for Fibrosis

    LIFESTYLE 

  • 2
    GLP-1 Drugs Like Ozempic Might Cut Cancer Risk Too, Study Finds

    LIFESTYLE 

  • 3
    New Brain Cancer Drug Taps Into the Body's Internal Clock

    LIFESTYLE 

  • 4
    How What You Eat Affects Your Mouth—And the Rest of Your Body

    LIFESTYLE 

  • 5
    Fatigue Fighters? Scientists Zero In on Hidden Energy Regulators

    LIFESTYLE